Stock AJANTPHARM AJANTA PHARMA LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Company Ajanta Pharma Limited

Equities

AJANTPHARM

INE031B01049

Pharmaceuticals

Market Closed - NSE India S.E.
Other stock markets
 07:42:29 2024-04-30 EDT 		5-day change 1st Jan Change
2,215 INR +0.13% Intraday chart for Ajanta Pharma Limited +5.93% +6.33%
04-26 Ajanta Pharma Limited?s Board intends to launch an Equity Buyback on May 2, 2024. CI
02-02 Ajanta Pharma Posts Gains in Fiscal Q3 Consolidated Net Profit MT

Business Summary

Ajanta Pharma Limited is an India-based specialty pharmaceutical company. The Company provides a comprehensive range of specialty branded generic products targeting a broad range of chronic and acute therapies. The Company is engaged in the manufacturing and sale of branded generic and generic pharmaceutical products. It has a wide range of therapeutic segments, such as cardiology, anti-diabetes, ophthalmology, dermatology, antibiotic, anti-malarial, pain, respiratory, gynecology, pediatric and general health products. Its branded generics business is spread across India, the rest of Asia, and Africa. Its business also consists of two verticals: United States generics and institutional business in Africa. Its ophthalmology products include Bimat (anti glaucoma), Nepaflam (anti-inflammatory), Softdrops (lubricant), and Olopat (anti-allergic). The Company's cardiology products include MET XL, Atorfit CV, Antihypertensive Cinod, Rosutor Gold, Dapalex and Vilatin.

Number of employees: 7,713

Sales per Business

INR in Million2022Weight2023Weight Delta
Pharmaceuticals
100.0 %
33,410 100.0 % 37,426 100.0 % +12.02%

Sales per region

INR in Million2022Weight2023Weight Delta
Emerging Markets
40.9 %
14,000 42.6 % 15,155 40.9 % +8.25%
India
31.7 %
9,822 29.9 % 11,740 31.7 % +19.53%
United States
22.3 %
6,959 21.2 % 8,278 22.3 % +18.96%
Africa
5.1 %
2,061 6.3 % 1,902 5.1 % -7.70%

Managers

Managers TitleAgeSince
Rajesh Mannalal Agrawal CEO
 Chief Executive Officer 48 98-12-31
Yogesh Mannalal Agrawal CEO
 Chief Executive Officer 52 95-12-31
Arvind K. Agrawal DFI
 Director of Finance/CFO 59 98-04-22
Gaurang C. Shah CMP
 Compliance Officer - -
Madhusudan Bhagwanda Agrawal BRD
 Director/Board Member 69 72-12-31

Members of the board

Members of the board TitleAgeSince
Yogesh Mannalal Agrawal CEO
 Chief Executive Officer 52 95-12-31
Mannalal Bhagwandas Agrawal CHM
 Chairman 77 79-12-30
Chandrakant Mohanlal Khetan BRD
 Director/Board Member 78 08-10-19
Madhusudan Bhagwanda Agrawal BRD
 Director/Board Member 69 72-12-31
Anjana Grewal BRD
 Director/Board Member 70 14-06-12
Prabhakar Ramchandra Dalal BRD
 Director/Board Member 71 14-06-12
Rajesh Mannalal Agrawal CEO
 Chief Executive Officer 48 98-12-31
Hariharan Kalpati Vishwanathan BRD
 Director/Board Member 78 13-04-29

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 125,915,655 63,352,944 ( 50.31 %) 0 50.31 %

Shareholders

NameEquities%Valuation
Rajesh Mannalal Agrawal
14.48 %
18,233,039 14.48 % 489 M ₹
Yogesh Mannalal Agrawal
14.48 %
18,233,038 14.48 % 489 M ₹
Ravi P Agrawal
13.24 %
16,671,623 13.24 % 447 M ₹
Ayush M Agrawal
11.33 %
14,267,664 11.33 % 383 M ₹
Gabs Investments Pvt Ltd.
9.997 %
12,588,393 9.997 % 338 M ₹
UTI Asset Management Co. Ltd. (Investment Management)
5.573 %
7,016,943 5.573 % 188 M ₹
Nippon Life India Asset Management Ltd. (Invt Mgmt)
2.984 %
3,756,806 2.984 % 101 M ₹
Ganga Exports Import International
2.684 %
3,379,297 2.684 % 91 M ₹
Kotak Mahindra Asset Management Co. Ltd.
1.240 %
1,561,468 1.240 % 42 M ₹
HDFC Asset Management Co. Ltd. (Invt Mgmt)
1.042 %
1,312,430 1.042 % 35 M ₹

Company contact information

Ajanta Pharma Ltd.

Ajanta House Charkop

400067, Mumbai

+91 22 6606 1000

http://www.ajantapharma.com
address Ajanta Pharma Limited(AJANTPHARM)

Sector

Healthcare
Pharmaceuticals & Medical Research
Pharmaceuticals
Pharmaceuticals
Generic Pharmaceuticals

Sales per region

Ratings for Ajanta Pharma Limited

Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
2,215 INR
Average target price
2,271 INR
Spread / Average Target
+2.52%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Generic Pharmaceuticals

1st Jan change Capi.
AJANTA PHARMA LIMITED Stock Ajanta Pharma Limited
+6.33% 3.34B
SUN PHARMACEUTICAL INDUSTRIES LTD. Stock Sun Pharmaceutical Industries Ltd.
+19.27% 43.18B
OTSUKA HOLDINGS CO., LTD. Stock Otsuka Holdings Co., Ltd.
+24.05% 23.23B
SANDOZ GROUP AG Stock Sandoz Group AG
+15.11% 14.6B
ZYDUS LIFESCIENCES LIMITED Stock Zydus Lifesciences Limited
+38.36% 11.5B
ONO PHARMACEUTICAL CO., LTD. Stock Ono Pharmaceutical Co., Ltd.
-7.63% 6.79B
THE MEDICINES COMPANY Stock The Medicines Company
-0.05% 6.79B
STADA ARZNEIMITTEL Stock STADA Arzneimittel
-8.87% 5.73B
ASPEN PHARMACARE HOLDINGS LIMITED Stock Aspen Pharmacare Holdings Limited
+10.21% 5.31B
SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. Stock Shenzhen Salubris Pharmaceuticals Co., Ltd.
-2.27% 4.81B
Generic Pharmaceuticals
  1. Stock Market
  2. Equities
  3. AJANTPHARM Stock
  4. Company Ajanta Pharma Limited